fda glp-1 warning letters november 2025 warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain Congress Introduces SAFE Drugs Act

While Alnylams Phase III APOLLO-B study hit both key primary and secondary endpoints, the FDA stated in the documents that the effects of patisiran compared to placebo on both endpoints were small, of questionable clinical meaningfulness, and may not be detectable by patients. Major discussion points during the adcomm meeting included whether these key endpoints were appropriate to ascertain clinical meaningfulness in the ATTR-CM population, and panelists expressed varying opinions on whether the magnitude of the benefit seen in trial data was clinically meaningful

However, several studies seem to indicate that Tregs may oppose the progression of diabetic complications by mitigating insulin resistance, atherosclerosis, and damage to target organs (as in kidney disease)

Great product

A survey conducted in August found that more than 80% of Americans had heard at least a little bit about semaglutide, while about one-third had either tried it or expressed interest in doing so

Activation of GLP-1R induces cellular response to neuroprotection, neurodevelopment, memory formation, cell growth, synapse growth, repair, and regeneration, increases neurotransmitters release, and activates Ca 2+ channels

When its blood supply is compromised, it can lead to significant visual impairment